Chronic Inflammation: What Actually Drives It, and Which Supplements Have Real Evidence

Inflammation is not one thing. It is two, and they run in opposite directions.

Acute inflammation heals: an injury swells, gets hot, hurts, and resolves over days. Chronic inflammation is a low-grade signal that never switches off, produces few symptoms, and tracks quietly with the long-term risks people worry about.

Most bad supplement advice starts with one mistake: treating those two as the same problem.

Table of Contents

• Acute vs Chronic Inflammation: Why the Difference Matters
• What Actually Drives Chronic Inflammation
• Which Supplements Have Real Evidence
• Omega-3 (EPA and DHA)
• Curcumin
• Vitamin D
• Ginger
• Quercetin
• Resveratrol
• What You Can Actually Measure
• How Long This Actually Takes
• What We Recommend
• Frequently Asked Questions
• References
• Important Note

Acute vs Chronic Inflammation: Why the Difference Matters

Acute inflammation is a repair crew. It arrives fast, sends blood flow and immune cells to the damaged tissue, finishes the job, and shuts itself down. It is self-limiting. Redness, heat, swelling, and pain are signs that it is working.

Chronic inflammation runs low and slow for months or years, and you usually cannot feel it. There is no resolution phase, because nothing is resolving and the driver keeps firing.

Conflating the two is where most supplement advice goes wrong. If inflammation is one thing, anything marketed to "fight inflammation" sounds like it should apply to you. A supplement that modulates one pathway cannot clear a driver that repeats every day.

The useful question is not what lowers inflammation. It is what is driving yours, and whether a supplement can even reach it.

What Actually Drives Chronic Inflammation

Ranking drivers by how much they move a measured marker is more useful than ranking them by how dramatic they sound.

1. Ultra-processed food. In 2,018 adults, every 100 g per day increase in ultra-processed food intake was associated with a 4.0% higher hs-CRP (95% CI 2.1 to 5.9%), and part of that held up independently of BMI [18]. The finding is cross-sectional: association, not cause.
2. Physical inactivity. Across 83 trials and 3,769 people, exercise training lowered CRP with a mean effect size of 0.26 (95% CI 0.18 to 0.34) [19]. The drop was larger when BMI also fell (effect size 0.38), but a significant improvement still occurred without any weight loss (effect size 0.19) [19].
3. Sleep disturbance. Across 72 studies and more than 50,000 people, sleep disturbance was associated with higher CRP (effect size 0.12) and higher IL-6 (effect size 0.20) [12]. But neither experimental sleep deprivation nor sleep restriction moved circulating CRP, IL-6, or TNF-alpha [12]. At the cellular level, though, partial sleep deprivation raised monocyte IL-6 and TNF-alpha production, with the authors' bioinformatic analysis pointing to NF-kB signaling [13]. Sleep and inflammation run both ways [14].

1. Visceral fat. No single comparable effect size, so it is not charted above, and it may matter more than any of them. In 1,250 Framingham Heart Study participants, visceral fat stayed significantly associated with CRP even after BMI and waist circumference entered the model [15]. Fat tissue is metabolically active, not inert.
2. Overall dietary pattern. In 164 adults at high cardiovascular risk, a Mediterranean diet with extra virgin olive oil or nuts reduced CRP and IL-6 over 12 months compared with a low-fat diet [20].
3. Gut permeability. In a mouse model, four weeks of high-fat feeding raised plasma lipopolysaccharide two to three times, a threshold the authors called metabolic endotoxemia [16]. A follow-up mouse study found the same diet increased intestinal permeability and reduced tight-junction gene expression [17]. Both are mouse studies, cited as mechanism, not as human outcomes. For the enzyme category itself, see our systemic enzymes guide.

The three drivers with a quantifiable effect are ultra-processed food, exercise, and sleep disturbance. None of them is a supplement.

Which Supplements Have Real Evidence

Supplements act at the margins, on specific pathways. They modulate a signal; they do not remove a driver. Each entry carries the dose studied and one limitation.

Omega-3 (EPA and DHA)

Omega-3 fats build into cell membranes and shift the signaling molecules made from them, which is why the effect shows up in membranes rather than in a single blood draw [7].

A dose-response meta-analysis of 40 randomized trials found CRP fell significantly up to 1,200 mg per day of combined EPA and DHA in people with cardiovascular disease, metabolic syndrome, or hypertension [6]. The limitation sits in the same paper: no significant CRP reduction appeared in overweight and obese participants [6]. Our omega-3 benefits guide covers the wider picture.

Curcumin

Curcumin acts on the NF-kB pathway, the same route the sleep data pointed to. An updated meta-analysis found CRP fell 3.67 mg/L versus placebo (95% CI -6.96 to -0.38) [8].

The counterintuitive part: the strongest effects appeared at 1,000 mg per day or less, and CRP dropped significantly after more than 10 weeks [8].

The limitation is a well-designed trial that failed. In 62 patients taking 3 g per day after surgery, recurrence was 58% on curcumin versus 68% on placebo, not a significant difference, and a higher proportion of the curcumin group had a severe recurrence [9]. Our curcumin benefits guide covers the formulation question.

Vitamin D

Vitamin D signals through receptors on immune cells. A meta-analysis of 13 randomized trials in 1,955 overweight and obese adults with deficient or insufficient baseline vitamin D found supplementation did not influence CRP (p=0.15), TNF-alpha (p=0.31), or IL-6 (p=0.71) [10].

Patients with inflammatory bowel disease had 64% higher odds of vitamin D deficiency than controls [11]. That is association, not proof of cause, and it is the trap: low vitamin D travels with inflammatory conditions, which is not the same as supplementing fixing them.

Ginger

Ginger acts on cytokine signaling. A meta-analysis of nine studies found CRP fell 0.84 mg/L (95% CI -1.38 to -0.31) [21].

The dose studied was 1 g per day of ginger powder for 12 weeks, the regimen in a trial of 120 knee osteoarthritis patients where hs-CRP fell more than placebo [22]. The limitation is heterogeneity: I² was 56.3%, which is substantial disagreement between the studies [21]. For joint comfort, see our joint pain and arthritis guide.

Quercetin

Quercetin acts on cytokine signaling and produces the smallest effect here. A meta-analysis of seven trials found CRP fell 0.33 mg/L (95% CI -0.50 to -0.15) [23].

The dose threshold was 500 mg per day or more, and the effect reached significance in trials where baseline CRP was already below 3 mg/L [23]. In other words, it showed up in people whose inflammation was already low.

Resveratrol

Resveratrol shares the cytokine-signaling territory with quercetin, and it is the clearest case of evidence contradicting itself. One meta-analysis of 10 randomized trials found no significant effect on CRP (p=0.731) [24]. A later one of 35 trials found resveratrol did reduce hs-CRP by 0.40 mg/L and CRP by 0.31 mg/L, at 500 mg per day or more and 10 weeks or more [25]. The limitation is that the same researcher co-authored both papers [24][25].

What You Can Actually Measure

The signs of chronic inflammation rarely show up in how you feel. They show up in a blood test, which is useful, because a number can be tracked.

• hs-CRP (high-sensitivity C-reactive protein). In 28,263 healthy postmenopausal women, hs-CRP was the strongest univariate predictor of cardiovascular events among 12 markers tested, with a relative risk of 4.4 for the highest versus lowest quartile [1].
• It is not just a cholesterol rerun. CRP and LDL correlate at only r=0.08, and risk climbed more steeply across CRP quintiles (1.4, 1.6, 2.0, 2.3) than across LDL quintiles [2]. The assay is widely available [4] and has entered primary-prevention guidelines [5].
• The Omega-3 Index. It measures the EPA and DHA built into your red blood cell membranes, as a percentage. An index of 8% or above was associated with the greatest cardioprotection, and 4% or below with the least [7].

The honest counterweight: across 52 studies and 246,669 people, adding CRP to a conventional risk model moved the C-index by 0.0039 and net reclassification by 1.52% [3]. Real, but modest: a good marker to track within yourself, a poor verdict on its own.

How Long This Actually Takes

Supplement marketing timelines describe how fast you feel something. That is the wrong clock. The question is how long a marker takes to move.

• Curcumin: CRP fell significantly after more than 10 weeks [8].
• Resveratrol: effects appeared at 10 weeks or more [25].
• Ginger: 12 weeks in the knee osteoarthritis trial [22].
• Dietary pattern: 12 months for the Mediterranean diet to reduce CRP and IL-6 [20].

Ten to twelve weeks is the shortest trial length where the marker change showed up, and it only means anything if you measured the marker before you started.

Symptom relief and marker change run on different clocks, and the marker is slower. Our guide to how long supplements take to work covers the general version.

What We Recommend

Two formulas are worth naming here, both stocked by the Agape Nutrition team. Neither one removes a driver, and neither is a reason to skip a baseline measurement if you plan to track anything.

Enzyme Science Enzyme Defense Pro: $49.49

A proteolytic enzyme blend of serrapeptase, nattokinase, catalase, and protease, with 1,000 IU of vitamin D3 and L-lysine. Take one capsule daily on an empty stomach, at least two hours after a meal.

Researched Nutritionals CytoQuel: $64.98

One blend built on CurcuWIN turmeric extract, with N-acetyl cysteine, black tea extract, tocotrienols, and resveratrol. Researched Nutritionals formulates it to support healthy cytokine production. It is the turmeric-based formula in the catalog. Take three capsules once per day with a meal. Sensitive patients may start with one capsule per day with a meal for the first week, then move up to three capsules per day in week two and beyond.

Frequently Asked Questions

What is a normal CRP level?

There is no single normal CRP level. The studies here stratify it rather than define a range, and the quercetin meta-analysis used 3 mg/L as its cut point [23]. Your lab reports its own reference range.

What is the fastest way to lower CRP?

Not the fastest way. The biggest levers here are fat mass, diet, and exercise training. Exercise lowered CRP across 83 trials, and it still worked in people who lost no weight [19].

Do anti-inflammatory supplements work if you sleep badly?

Sleep disturbance is associated with higher CRP and IL-6 [12], yet experimental sleep deprivation did not move circulating markers at all [12]. Fix the sleep first.

How long until omega-3 lowers inflammation?

The CRP benefit plateaus at 1,200 mg per day of combined EPA and DHA, and it did not appear in overweight and obese participants [6]. Expect a slower clock than a blood level suggests: the Omega-3 Index reflects longer-term intake rather than a single day's dose, because it is built from the EPA and DHA held in red blood cell membranes [7].

Can you take curcumin with ibuprofen?

The trials in this article tested curcumin on its own, not alongside pain relievers, so there is no evidence here for or against combining them. If you take a blood thinner or another anti-inflammatory medicine, check with your pharmacist before adding curcumin.

Is turmeric or curcumin better?

The trials that moved CRP used standardized curcumin, at 1,000 mg per day or less, for more than 10 weeks [8]. Culinary turmeric is a spice, not a dose.

Does chronic inflammation cause weight gain?

In mice, continuous lipopolysaccharide infusion reproduced weight gain and adipose inflammation [16], so the direction runs both ways in the laboratory. In humans the data shows association, not cause: visceral fat was associated with higher inflammatory markers in a cross-sectional study of 1,250 people [15].

References

1. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836-843. doi:10.1056/nejm200003233421202
2. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557-1565. doi:10.1056/nejmoa021993
3. Emerging Risk Factors Collaboration; Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310-1320. doi:10.1056/nejmoa1107477
4. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103(13):1813-1818. doi:10.1161/01.cir.103.13.1813
5. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Int J Cardiol. 2013;168(6):5126-5134. doi:10.1016/j.ijcard.2013.07.113
6. Amlashi MA, Payahoo A, Maskouni SJ, et al. Dose-dependent effects of omega-3 polyunsaturated fatty acids on C-reactive protein concentrations in cardiometabolic disorders: a dose-response meta-analysis of randomized clinical trials. Inflammopharmacology. 2025 (online ahead of print). doi:10.1007/s10787-025-01744-8
7. Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med. 2004;39(1):212-220. doi:10.1016/j.ypmed.2004.02.030
8. Gorabi AM, Abbasifard M, Imani D, et al. Effect of curcumin on C-reactive protein as a biomarker of systemic inflammation: An updated meta-analysis of randomized controlled trials. Phytother Res. 2022;36(1):226-237. doi:10.1002/ptr.7284
9. Bommelaer G, Laharie D, Nancey S, et al. Oral curcumin no more effective than placebo in preventing recurrence of Crohn's disease after surgery in a randomized controlled trial. Clin Gastroenterol Hepatol. 2020;18(7):1573-1581. doi:10.1016/j.cgh.2019.08.041
10. Jamka M, Woźniewicz M, Walkowiak J, Bogdański P, Jeszka J, Stelmach-Mardas M. The effect of vitamin D supplementation on selected inflammatory biomarkers in obese and overweight subjects: a systematic review with meta-analysis. Eur J Nutr. 2016;55(6):2163-2176. doi:10.1007/s00394-015-1089-5
11. Del Pinto R, Pietropaoli D, Chandar AK, Ferri C, Cominelli F. Association between inflammatory bowel disease and vitamin D deficiency: a systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21(11):2708-2717. doi:10.1097/mib.0000000000000546
12. Irwin MR, Olmstead R, Carroll JE. Sleep disturbance, sleep duration, and inflammation: a systematic review and meta-analysis of cohort studies and experimental sleep deprivation. Biol Psychiatry. 2016;80(1):40-52. doi:10.1016/j.biopsych.2015.05.014
13. Irwin MR, Wang M, Campomayor CO, Collado-Hidalgo A, Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch Intern Med. 2006;166(16):1756-1762. doi:10.1001/archinte.166.16.1756
14. Irwin MR. Sleep and inflammation: partners in sickness and in health. Nat Rev Immunol. 2019;19(11):702-715. doi:10.1038/s41577-019-0190-z
15. Pou KM, Massaro JM, Hoffmann U, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation. 2007;116(11):1234-1241. doi:10.1161/circulationaha.107.710509
16. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-1772. doi:10.2337/db06-1491
17. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470-1481. doi:10.2337/db07-1403
18. Lane MM, Lotfaliany M, Forbes M, et al. Higher ultra-processed food consumption is associated with greater high-sensitivity C-reactive protein concentration in adults: cross-sectional results from the Melbourne Collaborative Cohort Study. Nutrients. 2022;14(16):3309. doi:10.3390/nu14163309
19. Fedewa MV, Hathaway ED, Ward-Ritacco CL. Effect of exercise training on C reactive protein: a systematic review and meta-analysis of randomised and non-randomised controlled trials. Br J Sports Med. 2017;51(8):670-676. doi:10.1136/bjsports-2016-095999
20. Casas R, Sacanella E, Urpí-Sardà M, et al. The effects of the Mediterranean diet on biomarkers of vascular wall inflammation and plaque vulnerability in subjects with high risk for cardiovascular disease. A randomized trial. PLoS One. 2014;9(6):e100084. doi:10.1371/journal.pone.0100084
21. Mazidi M, Gao HK, Rezaie P, Ferns GA. The effect of ginger supplementation on serum C-reactive protein, lipid profile and glycaemia: a systematic review and meta-analysis. Food Nutr Res. 2016;60:32613. doi:10.3402/fnr.v60.32613
22. Naderi Z, Mozaffari-Khosravi H, Dehghan A, Nadjarzadeh A, Huseini HF. Effect of ginger powder supplementation on nitric oxide and C-reactive protein in elderly knee osteoarthritis patients: a 12-week double-blind randomized placebo-controlled clinical trial. J Tradit Complement Med. 2016;6(3):199-203. doi:10.1016/j.jtcme.2014.12.007
23. Mohammadi-Sartang M, Mazloom Z, Sherafatmanesh S, Ghorbani M, Firoozi D. Effects of supplementation with quercetin on plasma C-reactive protein concentrations: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2017;71(12):1333-1339. doi:10.1038/ejcn.2017.55
24. Sahebkar A, Serban C, Ursoniu S, et al. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors: results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2015;189:47-55. doi:10.1016/j.ijcard.2015.04.008
25. Gorabi AM, Aslani S, Imani D, Razi B, Sathyapalan T, Sahebkar A. Effect of resveratrol on C-reactive protein: An updated meta-analysis of randomized controlled trials. Phytother Res. 2021;35(12):6806-6814. doi:10.1002/ptr.7262

Important Note

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.